Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Germany: Cognex.

North America

USA: Cognex (d).

Latin America

Argentina: Talem.

Drug combinations


Tacrine Hydrochloride: C~13~H~14~N~2~ HCl H~2~O. Mw: 252.74. (1) 9-Acridinamine, 1,2,3,4-tetrahydro-, monohydrochloride; (2) 9-Amino-1,2,3,4-tetrahydroacridine monohydrochloride. CAS-1684-40-8; CAS-321-64-2 (tacrine)(1988).

Pharmacologic Category

Parasympathomimetic (Cholinergic) Agents. Anti-Dementia Agents; Cholinesterase Inhibitors. (ATC-Code: N06DA01).

Mechanism of action

Elevates acetylcholine in cerebral cortex by slowing degradation of acetylcholine.

Therapeutic use

Treatment of mild-to-moderate dementia of the Alzheimer’s type.

Pregnancy and lactiation implications

Use with caution during pregnancy. Not recommended in nursing women.

Unlabeled use

Lewy body dementia.


Hypersensitivity to tacrine, acridine derivatives, or any component of the formulation. Patients previously treated with tacrine who developed jaundice.

Warnings and precautions

Use of tacrine has been associated with elevations in serum transaminases. Use extreme caution in current evidence of history of abnormal liver function tests. May cause loose stools, nausea and/or vomiting. May be associated with neutropenia. Cholinesterase inhibitors may have vagotonic effects which may cause bradycardia and/or heart block with or without history of cardiac disease. Tacrine may cause bradycardia and/or heart block (use with caution in sick-sinus syndrome, bradycardia, or conduction abnormalities). Use with caution in risk of ulcer disease (e.g. previous history or NSAID use); may increase gastric acid secretion, in COPD and/or asthma, in history of seizure disorder, and in bladder outlet obstruction or prostatic hyperplasia. Cholinomimetics may cause or worsen outflow obstructions, including possible exacerbation of BPH symptoms. May exaggerate neuromuscular blockade effects of depolarizing neuromuscular-blocking agents such as succinylcholine. Abrupt discontinuation or dosage decrease may worsen cognitive function.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart